References
- Lauritsen K, Bytzer P, Hansen J, Bekker C, Rask-Madsen J. Comparison of ranitidine and high-dose antacid in the treatment of prepyloric or duodenal ulcer. A double-blind controlled trial. Scand J Gastroenterol 1985; 20: 123–128
- Ström M, Berstad A, Bodemar G, Walan A. Results of short- and long-term cimetidine treatment in patients with jwtapyloric ulcers, with special reference to gastric acid and pepsin secretion. Scand J Gastroenterol 1986; 21: 521–530
- Lauritsen K, Rune S J, Wulff H R, Olsen J H, Laur-Sen L S, Havelund T, Astrup L, et al. Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. Gut 1988; 29: 249–253
- Halter F, Eigenmann F. Is it more difficult to treat prepyloric ulcers?. Aliment Pharmacol Ther 1987; 1: 4333–4388
- Collins P W. Development and therapeutic role of synthetic prostaglandins in peptic ulcer disease. J Med Chem 1986; 29: 437–443
- Monk J P, Clissold S P. Misoprostol. A preliminary review of its pharmacodynamic and pharmokinetic properties and therapeutic efficacy in the treatment of peptic ulcer disease. Drugs 1987; 33: 1–30
- Goa K L, Monk J P. Enprostil. A preliminary review of its pharmacodynamic and pharmakokinetic properties and theraoeutic efficacy in the treatment of peptic ulcer dise'ase. Drugs 1987; 34: 539–559
- Miller T A. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601–G623
- Rask-Madsen J, Lauritsen K. Enhancement of mucosal defence by prostaglandins. Rationale and clinical experience in ulcer disease. Scand J Gastroenterol 1987; 22(suppl 128)34–42
- Shriver D A, Rosenthale M E, Kluender H C, Schut R N, McGuire J L, Hong E. Pharmacology of rio-prostil, a new gastric cytoprotective/antisecretory agent. Arzneimittelforsch 1985; 35: 839–843
- Demol P, Wingender W, Weihrauch T R. Inhibition of gastric secretion in man by rioprostil, a new synthetic methyl prostaglandin E1 [Abstract]. Gas-troenterology 1984; 86: 1061
- Radwin M, Drewniak S, Matloff D, Wright S, McCormack G, Simon D, Lewis G, et al. Bedtime rioprostil protects the gastroduodenal mucosa from aspirin induced damage [Abstract]. Gastroenter-ology 1986; 90: 1596
- Katz L B, Shriver D A, Capetola R J, Argentieri D C, Porter M C, Jasty V, Hartnagel R E, et al (1986) Rioprostil prevents aspirin-induced gastric bleeding in dogs and arthritic rats [Abstract]. Abstract Book: 6th International Conference on Prostaglandins and Related Compounds, Florence, June, 3–61986. Fon-dazione Giovanni Lorenzini, Milan, 228
- Fleiss J L. Statistical methods for rates and proportions. John Wiley & Sons, New York 1981
- O'Brien P C, Fleming T R. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–556
- Lauritsen K, Rask-Madsen J. Review: clinical trials in peptic ulcer disease—problems of methodology and interpretation. Aliment Pharmacol Ther 1987; 1: 97–123
- Dammann H G, Walter T A, Miiller P, Simon B. Night-time rioprostil versus ranitidine in duodenal ulcer healing [Letter]. Lancet 1986; 2: 335–336
- Lauritsen K, Rask-Madsen J. Prostaglandin analogues. Baillières Clin Gastroenterol 1988; 2: 621–628
- Lauritsen K, Laursen L S, Havelund T, Bytzer P, Rask-Madsen J. Controlled trial of arbaprostil in bleeding peptic ulcer. Br Med J 1985; 291: 1093
- Lauritsen K, Laursen L S, Havelund T, Bytzer P, Svendsen L B, Rask-Madsen J. Enprostil and ranitidine in duodenal ulcer healing: double blind comparative trial. Br Med J 1986; 292: 864–866
- Lauritsen K, Havelund T, Laursen L S, Bytzer P, Kjaergaard J, Rask-Madsen J. Enprostil and ranitidine in prevention of duodenal ulcer relapse: one year double blind comparative trial. Br Med J 1987; 294: 932–934